RKVTF (Rakovina Therapeutics) Other Current Receivables: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RKVTF Rakovina Therapeutics Inc RKVTF
27 GF Score
Price $0.07
! 1 Warning Sign
View Full Analysis

What is Rakovina Therapeutics Other Current Receivables?

Rakovina Therapeutics RKVTF 27 Other Current Receivables is $0.00 Mil as of Mar. 2026. GuruFocus rates RKVTF with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

Rakovina Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.00 Mil.

Rakovina Therapeutics Other Current Receivables Related Terms

Rakovina Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Rakovina Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rakovina Therapeutics Other Current Receivables Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
0.00 0.00 0.00 0.00 0.00

Rakovina Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RKVTF
27GF Score
Rakovina Therapeutics Inc RKVTF
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rakovina Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.00 Mil mean?
Rakovina Therapeutics (RKVTF) has a Other Current Receivables of $0.00 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Rakovina Therapeutics and its competitors.
Is Rakovina Therapeutics' Other Current Receivables too high?
Rakovina Therapeutics' current Other Current Receivables is $0.00 Mil. Overall, Rakovina Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Rakovina Therapeutics' Other Current Receivables compare to VRTX and REGN?
Rakovina Therapeutics' Other Current Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Rakovina Therapeutics and its competitors. Rakovina Therapeutics's current Other Current Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rakovina Therapeutics stock overvalued right now?
Rakovina Therapeutics (RKVTF) has a current Other Current Receivables of $0.00 Mil. The current Other Current Receivables is $0.00 Mil. Rakovina Therapeutics' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Rakovina Therapeutics (RKVTF), the current Other Current Receivables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rakovina Therapeutics Business Description

Other Exchanges 7JO0:GermanyRKV:Canada
Address 999 West Broadway, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a greater pace. The company has established a pipeline of distinctive DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Its drug development pipeline consists of candidates like kt-5000AI, kt-2000AI, and kt-3283, targeting solid tumours and PARP-resistant adult and childhood cancers.
27GF Score

Get the complete analysis for RKVTF

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07
Price